Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Peter Horby, Professor of Emerging Infectious Diseases and Global Health

A range of potential treatments have been suggested for COVID-19 but nobody knows if any of them will turn out to be more effective in helping people recover than the usual standard of hospital care which all patients will receive. The RECOVERY Trial is currently testing some of these suggested treatments: 

  • high-dose vs standard corticosteroids
  • empagliflozin (a drug for diabetes and heart and kidney disease)
  • sotrovimab (a monoclonal antibody treatment against the spike protein)
  • molnupiravir (an antiviral treatment)
  • paxlovid (an antiviral treatment)

Data from the trial are regularly reviewed so that any effective treatment can be identified quickly and made available to all patients. Please see our news page for results that RECOVERY has already found. The RECOVERY Trial team will constantly review information on new drugs and include promising ones in the trial.  

Letters from the Chief Medical Officers

The Chief Medical Officers of England, Wales, Scotland and Northern Ireland, and the NHS Medical Director, have written to all doctors strongly encouraging participation in the national randomised trials in COVID-19 of which RECOVERY is one. You can read the letters by following the links below. Please pass them on to your colleagues.

The importance of increasing recruitment

The importance of COVID-19 clinical trials

Recruiting patients for clinical trials for Covid-19 therapeutics

The RECOVERY Trial is registered at ISRCTN50189673 
EU Clinical Trials Register: EudraCT 2020-001113-21
Clinical NCT04381936